

Martina Garau

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2759877/publications.pdf>

Version: 2024-02-01

11
papers

319
citations

1307594

7
h-index

1372567

10
g-index

11
all docs

11
docs citations

11
times ranked

513
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward. <i>Value in Health</i> , 2019, 22, 1283-1288.	0.3	97
2	Using QALYs in Cancer. <i>Pharmacoeconomics</i> , 2011, 29, 673-685.	3.3	74
3	Comparing access to orphan medicinal products in Europe. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 95.	2.7	57
4	Can and should value-based pricing be applied to molecular diagnostics?. <i>Personalized Medicine</i> , 2013, 10, 61-72.	1.5	30
5	Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholdersâ€™ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL). <i>Pharmacoeconomics - Open</i> , 2018, 2, 153-163.	1.8	22
6	PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 90-98.	0.5	16
7	The future of comparative effectiveness and relative efficacy of drugs: an international perspective. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 419-427.	1.4	8
8	Futurescapes: expectations in Europe for relative effectiveness evidence for drugs in 2020. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 401-418.	1.4	5
9	IS THE LINK BETWEEN HEALTH AND WEALTH CONSIDERED IN DECISION MAKING? RESULTS FROM A QUALITATIVE STUDY. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 449-456.	0.5	4
10	Using MCDA as a Decision Aid in Health Technology Appraisal for Coverage Decisions: Opportunities, Challenges and Unresolved Questions. , 2017, , 277-298.		4
11	Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB. <i>BMJ Global Health</i> , 2020, 5, e002061.	4.7	2